EV
1 product
16 abstracts
2 targets
Target
neoantigen peptidesTarget
neoantigensAbstract
Enfortumab vedotin (EV) in triple-negative breast cancer (TNBC) and HR+/HER2- breast cancer (BC) cohorts of EV-202.Org: Dana-Farber Cancer Institute, University of Wisconsin, University of California Irvine, University of Colorado Denver Department of Radiation Oncology, Perlmutter Cancer Center, NYU Langone Health,
Abstract
Enfortumab vedotin (EV) in previously treated gastric/esophageal cancers cohorts of EV-202.Org: Kashiwa, Japan, Cape Coral, FL, Bothell, WA,
Abstract
Results of a phase 2 study of evorpacept (E, ALX148), cetuximab (C), and pembrolizumab (P) in patients with refractory microsatellite stable metastatic colorectal cancer (MSS CRC).Org: University of Colorado Cancer Center, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Department of Medicine, Icahn School of Medicine at Mount Sinai, University of Colorado Anschutz Medical Campus, Inova Schar Cancer Institute,
Abstract
Clinical outcomes of sacituzumab govitecan (SG) after prior exposure to enfortumab vedotin (EV) in patients with metastatic urothelial carcinoma (mUC).Org: Memorial Sloan Kettering Cancer Center, Barts Cancer Institute, Queen Mary University of London, Genitourinary Oncology Service, Weill Cornell Medical College University,
Abstract
Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) for metastatic urothelial carcinoma (mUC) treatment-experienced (DAD) and with pembrolizumab (P) in treatment naïve UC (DAD-IO).Org: Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Dana-Farber Cancer Institute, AdventHealth Cancer Institute, The Lank Center for Genitourinary Oncology,
Abstract
Enfortumab vedotin (EV) in non-squamous and squamous non–small cell lung cancer (NSCLC) cohorts of EV-202.Org: Georgia Cancer Specialists/Northside Hospital Atlanta, NextPoint Therapeutics, VA Medical Center,
Abstract
Enfortumab vedotin (EV) with pembrolizumab (P) versus chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Analysis of cisplatin (cis)-eligible population from EV-302/KEYNOTE-A39.Org: Barts Cancer Centre, QMUL, London, United Kingdom, Genitourinary Oncology, Memorial Sloan Kettering Cancer Center; Weill Cornell Medical College, New York, NY, Integrated Cancer Center Ghent, AZ Maria Middelares, Ghent and Center for Oncological Research (CORE), Integrated Personalised and Precision Oncology Network (IPPON), University of Antwerp, Antwerp, Belgium, Charing Cross Hospital, London, United Kingdom, University of California, Los Angeles Medical Center, Los Angeles, CA,
Abstract
Enfortumab vedotin (EV) with pembrolizumab (P) versus chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Analysis of the cisplatin (cis)-ineligible population from EV-302/KEYNOTE-A39.Org: University of California Irvine Medical Center, Santa Creu i Sant Pau Hospital, Seattle Cancer Care Alliance, IDIVAL, Barts Cancer Centre QMUL,
Abstract
KEYNOTE-905/EV-303: A phase 3 study to evaluate the efficacy and safety of perioperative pembrolizumab or pembrolizumab plus enfortumab vedotin (EV) for muscle-invasive bladder cancer (MIBC).Org: Vita-Salute San Raffaele University, IRCCS San Raffaele Hospital and Scientific Institute, Milan, Italy, Eberhard Karls University of Tübingen, Tübingen, Germany, Icahn School of Medicine at Mount Sinai, New York, NY, Carolina Urologic Research Center, Myrtle Beach, SC,
Abstract
Independent biomarkers predictive of outcomes with enfortumab vedotin (EV) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study.Org: University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, University of California Irvine, MD Anderson Hematology/Oncology Fellowship, The Medical College of Wisconsin,
Abstract
A first-in-human trial of intravesical enfortumab vedotin (EV), an antibody-drug conjugate (ADC), in patients with non-muscle invasive bladder cancer (NMIBC): Interim results of a phase 1 study (EV-104).Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, UT Southwestern Medical Center, Hôpital Pitié-Salpêtrière, NYU Department of Urology, Perlmutter Cancer Center, New York University Langone Health,
Abstract
Enfortumab vedotin (EV) with or without pembrolizumab (P) in patients (pts) who are cisplatin-ineligible with previously untreated locally advanced or metastatic urothelial cancer (la/mUC): Additional 3-month follow-up on cohort K data.Org: University of California, San Francisco Medical Center, University of North Carolina, Lineberger Comprehensive Cancer Center, University of Chicago, Yale Cancer Center, Yale School of Medicine, New Haven, CT, Duke Cancer Institute,
Abstract
A phase III randomized trial of eribulin (E) with or without gemcitabine vs standard of care (SOC) for metastatic urothelial carcinoma (UC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937.Org: SWOG Statistics and Data Management Center, Seattle, WA, University of California Davis Comprehensive Cancer Center, Fred Hutchinson Cancer Research Center, SWOG Cancer Research Network, Baylor College of Medicine,
Abstract
Biomarkers of response to sacituzumab govitecan (SG) and efficacy after treatment with enfortumab vedotin (EV) in advanced urothelial carcinoma (aUC): Analysis of the UNITE study.Org: University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, MD Anderson Hematology/Oncology Fellowship, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, University of Washington and Fred Hutchinson Cancer Research Centre,
Abstract
Real-world use, dose intensity, and adherence to enfortumab vedotin (EV) in locally advanced or metastatic urothelial cancer (la/mUC).Org: Astellas Pharma Inc., Astellas Pharma, Abramson Cancer Center,
Abstract
Clinical efficacy analysis of patients (pts) with HER-2 expressing metastatic urothelial carcinoma (mUC) treated with enfortumab vedotin (EV).Org: MD Anderson Hematology/Oncology Fellowship, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Baylor College of Medicine, MD Anderson Cancer Center, University of Texas MD Anderson Cancer Center,
Product
EVX-01 + Pembrolizumab